|
|
|
|
Mesalamine Foam Can Replace Liquid Mesalamine Enemas for Ulcerative Colitis
_ Mesalamine Foam Can Replace Liquid Mesalamine Enemas for Ulcerative Colitis.
|
|
|
New Genetic Markers for Ulcerative Colitis Identified, Researchers Report in Nature Genetics
Discovery could improve understanding of disease process, lead to new therapies PITTSBURGH, January 4, 2008 An international team led by University of Pittsburgh School of Medicine researchers has identified genetic markers associated with...
|
|
|
New Genetic Markers For Ulcerative Colitis Identified, Researchers Report In Nature Genetics
An international team led by University of Pittsburgh School of Medicine researchers has identified genetic markers associated with risk for ulcerative colitis.The findings, which appear today as an advance online publication of the...
|
|
|
Researchers Identify Gene Markers For Ulcerative Colitis
Discovery could improve understanding of disease process, lead to new therapies An international team led by University of Pittsburgh School of Medicine researchers has identified genetic markers associated with risk for ulcerative colitis....
|
|
|
Does Cigarette Smoking Increase the Risk of Developing Ulcerative Colitis or Crohns Disease
Harris T - Although cigarette smoking seems to be protective against developing UC, the other risks associated with cigarettes far outweigh the possible benefits.Does Cigarette Smoking Increase the Risk of Developing Ulcerative ...
|
|
|
Genetic Markers Associated With Risk for Ulcerative Colitis Identified
-- Researchers have identified genetic markers associated with risk for ulcerative colitis.The findings are published early online and in an upcoming issue of the journal Nature Genetics. Richard H. Duerr, MD, University of Pittsburgh...
|
|
|
Discovery Could Improve Understanding Of Ulcerative Colitis, Lead To New Therapies
Also Included In: Genetics; Crohn's; GastroIntestinal / Gastroenterology email to a friend printer friendly view / write opinions rate article Current Article Ratings: Patient / Public: Health Professional: Article Opinions: An international...
|
|
|
Mild-to-moderate Active Ulcerative Colitis - Salix Receives FDA Complete Response Letter For Balsalazide Table
Salix Pharmaceuticals, Ltd.(NASDAQ:SLXP) today announced that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for balsalazide tablet studied as a...
|
|
|
Home Telemanagement for Patients with Ulcerative Colitis (UC HAT)
Cross RK et al.- Effective therapies exist to treat ulcerative colitis (UC); nonadherence, inadequate monitoring, and side-effects result in suboptimal outcomes. Patients with UC can be easily trained to use HAT, and patient acceptance...
|
|
|
FDA Denies Salix Pharmaceuticals, Ltd. (SLXP) Ulcerative Colitis Drug Approval
RALEIGH, N.C.--(BUSINESS WIRE)-- (NASDAQ:SLXP) today announced that the Company has received a complete response letter from the U.S.Food and Drug Administration (FDA) for its New Drug Application (NDA) for balsalazide tablet studied as a...
|
|
|
Salix Gets FDA's Complete Response Letter; Indicates Additional Clinical Trial For Ulcerative Colitis Drug App
(RTTNews) - Monday, Salix Pharmaceuticalthe U.S.Food and Drug Administration in its complete response letter to Salix Pharmaceuticals Ltd. (SLXP: News ), said that it could not approve the New Drug Application for balsalazide tablet...
|
|
|
Review Article: 5-aminosalicylate Formulations for the Treatment of Ulcerative Colitis -- Methods of Comparing
_ Review Article: 5-aminosalicylate Formulations for the Treatment of Ulcerative Colitis -- Methods of Comparing.
|
|
|
Studies in the area of colitis therapy reported from University of Seville, Department of Pharmacology
- (NewsRx.com) -- A report, 'Acute and chronic responses associated with adrenomedullin administration in experimental colitis,' is newly published data in Peptides (see also Colitis Therapy).'Adrenomedullin (AM) is a 52 amino acid...
|
|
|
Tumor Necrosis Factor and Colitis-Associated Colon Cancer
_ Tumor Necrosis Factor and Colitis-Associated Colon Cancer.
|
|
|
Oral Budesonide Maintains Remission in Collagenous Colitis
_ Oral Budesonide Maintains Remission in Collagenous Colitis.
|
|
|
Oral Budesonide Maintains Remission in Collagenous Colitis
_ Oral Budesonide Maintains Remission in Collagenous Colitis.
|
|
|
Lialda for Ulcerative Colitis
Pharmacy Author: M Medical and Pharmacy Editor: DRUG CLASS AND MECHANISM: Mesalamine is an oral drug used for treating ulcerative colitis.Lialda is mesalamine in a form that is slowly released in the intestine so that it can be given just...
|
|
|
Michael Karin, Professor At UCSD To Give Keynote Speech At 7th Cytokines And Inflammation Conference
Michael Karin, Professor of Pharmacology Tumor Growth Invasion and Metastasis at UCSD to Give Keynote Speech at GTCbio's 7th Cytokines and Inflammation Conference on January 29-30, 2009 in San Diego, CA Dr.Michael Karin, Professor of...
|
|
|
Mesalamine Foam Enema Versus Mesalamine Liquid Enema in Active Left-Sided Ulcerative Colitis
Cortot A et al.- A 4-wk treatment of 1 g mesalamine foam induced a clinical remission in 68% patients versus 73% with 1 g mesalamine liquid enema. Although the noninferiority of mesalamine foam could not be strictly demonstrated at W4...
|
|
|
Cost-Effectiveness of 5-Aminosalicylic Acid Therapy for Maintenance of Remission in Ulcerative Colitis
Yen EF et al.- Maintenance 5-ASA therapy decreases UC flares, but its cost may be substantial, depending on society's willingness to pay. If sulfasalazine can be tolerated and yields comparable benefits, sulfasalazine maintenance...
|
|
|
Ore Pharmaceuticals Announces Completion Of Multiple Ascending Dose GL1001 Clinical Phase 1 Trial
Ore Pharmaceuticals Inc.(NASDAQ: ORXE) today announced that it has completed dosing volunteer subjects in its multiple ascending dose clinical study of the Company's lead drug candidate, GL1001. The study, initiated in September, was a...
|
|
|
New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fi
Data presented this week by UCB at Advances in Inflammatory Bowel Diseases 2008, the Crohn's & Colitis Foundation's Clinical & Research Conference, demonstrated more than half (53.6%) of those moderate to severe Crohn's disease...
|
|
|
New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fi
Improved outcomes for fistula closures observed in PRECiSE 2 trial under maintenance therapy with stable dosing of CIMZIA(R) every four weeks HOLLYWOOD, Fla., Dec.5 /PRNewswire-FirstCall/ -- Data presented this week by UCB at Advances in...
|
|
|
Ore Pharmaceuticals Announces Completion of Multiple Ascending Dose GL1001 Clinical Phase 1 Trial; Presents GL
Pharmaceuticals Announces Completion of Multiple Ascending Dose GL1001 Clinical Phase 1 Presents GL1001 Preclinical Efficacy Results at Crohns and Colitis Foundation Conference: Financial - Finance My SearchSearch:New User?-...
|
|
|
New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fi
Improved outcomes for fistula closures observed in PRECiSE 2 trial under maintenance therapy with stable dosing of CIMZIA(R) every four weeks HOLLYWOOD, Fla., Dec.5 /PRNewswire-FirstCall/ -- Data presented this week by UCB at Advances in...
|
